10-Q: Precision BioSciences Reports Q2 2026 Results

Precision BioSciences reported its Q2 2026 financial results, highlighting progress in its gene editing programs PBGENE-HBV and PBGENE-DMD, while continuing to incur net losses.

Summary

• Precision BioSciences reported a net loss of $32.7 million for the three months ended June 30, 2026, and $51.1 million for the six months ended June 30, 2026.
• The company's cash, cash equivalents, and restricted cash stood at $112.4 million as of June 30, 2026.
• Research and development expenses decreased slightly to $12.4 million for Q2 2026 from $12.8 million in Q2 2025, and decreased to $25.5 million for the six months ended June 30, 2026 from $26.4 million in the prior year period.
• General and administrative expenses also decreased, to $6.8 million for Q2 2026 from $9.1 million in Q2 2025, and to $13.6 million for the six months ended June 30, 2026 from $17.7 million in the prior year period.
• The company presented positive preclinical data for PBGENE-DMD at the ASGCT 2026 Annual Meeting and clinical data for PBGENE-HBV at the EASL Congress 2026.
• The company expects its current cash and cash equivalents to be sufficient to fund operations through 2028.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to continued net losses, significant accumulated deficit, and reliance on future funding, despite progress in clinical programs.

Positives

• Presented positive clinical data for PBGENE-HBV at EASL Congress 2026, showing a 1-log reduction in cccDNA-derived transcripts in one patient and durable pgRNA undetectability in 100% of treated patients.
• Showcased positive preclinical data for PBGENE-DMD at ASGCT 2026, supporting evaluation in younger DMD patient populations.
• The company expects its cash runway to be sufficient to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028.
• Secured $7.5 million milestone payment from TG Therapeutics, including $5.25 million cash and $2.25 million for common stock purchase.

Negatives

• Reported a net loss of $32.7 million for the three months ended June 30, 2026, and $51.1 million for the six months ended June 30, 2026.
• Accumulated deficit increased to $579.3 million as of June 30, 2026.
• The fair value of warrant liability increased significantly to $36.7 million from $15.7 million at the end of 2025, resulting in a non-cash loss of $13.9 million for Q2 2026 and $21.0 million for the six months ended June 30, 2026.
• No revenue was recognized for the three months ended June 30, 2026, compared to $0.018 million in the prior year period.

Risks

• The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Substantial additional funding is required, and failure to raise sufficient capital could force the company to delay, reduce, or eliminate research programs and product development activities.
• The company is heavily dependent on the successful development and translation of its ARCUS genome editing platform, which is novel and has a limited operating history.
• Clinical trials are expensive, time-consuming, and have uncertain outcomes; failure to successfully conduct trials and obtain regulatory approval would substantially harm the business.
• Adverse public perception of genome editing technology could negatively impact developmental progress and commercial success.
• The company faces significant competition in a rapidly changing technological field, and competitors may develop safer or more effective products.
• The company's ability to manage growth and attract/retain qualified personnel is critical for future success.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.

Future Outlook

The company believes its existing cash and cash equivalents, fiscal discipline, and ATM facility availability will be sufficient to fund its operating expenses and capital expenditure requirements through 2028, including PBGENE-HBV and PBGENE-DMD data milestones. However, it acknowledges the need for substantial additional funding and the risks associated with obtaining it.

Management Comments

• The company continues to advance its Phase 1/2 FUNCTION-DMD clinical trial, with initial safety data expected by year-end 2026.
• The company expects to provide additional updates on the ELIMINATE-B trial progress by the end of 2026.
• Management believes that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of the ATM facility will be sufficient to fund operating expenses and capital expenditure requirements through 2028.

Industry Context

StockSavvy.ai notes that Precision BioSciences operates in the highly competitive and rapidly evolving gene editing and biotechnology sector. The company's focus on in vivo therapies for genetic and infectious diseases aligns with broader industry trends towards targeted genetic treatments. However, the significant capital requirements and long development timelines are characteristic of the industry, as are the inherent risks associated with clinical trials and regulatory approvals.

Comparison to Industry Standards

• Precision BioSciences' net loss of $51.1 million for the first six months of 2026 is substantial, but not uncommon for early-stage biotechnology companies investing heavily in R&D. Many companies in this sector operate at a loss for extended periods before achieving profitability.
• The company's cash runway projection through 2028 is a positive indicator, suggesting prudent financial management, though it remains dependent on future funding rounds.
• The progress reported in the PBGENE-HBV clinical trial, particularly the cccDNA reduction and pgRNA durability, represents a potentially significant advancement in treating chronic hepatitis B, a complex viral infection targeted by several industry players.

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience continued dilution if the company raises additional capital through equity financings.
• The company's reliance on future funding and its ongoing losses could impact investor confidence.
• Progress in clinical trials for PBGENE-HBV and PBGENE-DMD could lead to significant positive impacts for patients suffering from chronic hepatitis B and Duchenne muscular dystrophy, respectively, if successful.

Next Steps

• Continue enrolling additional patients in the ELIMINATE-B trial and collecting further biopsies and blood biomarker data.
• Inform selection of the optimal dosing schedule for Part 2 expansion of the ELIMINATE-B trial.
• Provide additional updates on the ELIMINATE-B trial progress by the end of 2026.
• Continue advancing the Phase 1/2 FUNCTION-DMD clinical trial, with initial safety data expected by year-end 2026.
• Continue to evaluate PBGENE-DMD in younger DMD patient populations.

Key Dates

Recommendation

While the company shows promising clinical data for its lead programs, the significant net losses, accumulated deficit, and continued reliance on future funding present substantial risks. The increase in warrant liability also negatively impacts the financial picture. The company's ability to execute on its clinical milestones and secure necessary funding will be critical for future value creation. Therefore, a 'hold' recommendation is appropriate, pending further clinical and financial developments.

Keywords

gene editing, ARCUS platform, hepatitis B, Duchenne muscular dystrophy, in vivo therapies, clinical trials, biotechnology, genome editing technology